z-logo
open-access-imgOpen Access
Diagnostic performance of new and classic CSF biomarkers in age-related dementias
Author(s) -
Francesca Marchegiani,
Giulia Matacchione,
Deborah Ramini,
Fiorella Marcheselli,
Rina Recchioni,
Tiziana Casoli,
Elisa Mercuri,
Marco Lazzarini,
Belinda Giorgetti,
Valentina Cameriere,
Susy Paolini,
Lucia Paciaroni,
Tommaso Rossi,
Roberta Galeazzi,
Rosamaria Lisa,
Anna Rita Bonfigli,
Antonio Domenico Procopio,
María De Luca,
Giuseppe Pelliccioni,
Fabiola Olivieri
Publication year - 2019
Publication title -
aging
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.473
H-Index - 90
ISSN - 1945-4589
DOI - 10.18632/aging.101925
Subject(s) - dementia , medicine , cerebrospinal fluid , disease , oncology , vascular dementia , biomarker , alzheimer's disease , cognitive impairment , pathology , biology , genetics
The identification of diagnostic-prognostic biomarkers of dementia has become a global priority due to the prevalence of neurodegenerative diseases in aging populations. The objective of this study was to assess the diagnostic performance of cerebrospinal fluid (CSF) biomarkers across patients affected by either Alzheimer's disease (AD), tauopathies other than AD (TP), or vascular dementia (VD), and cognitively normal subjects (CNS). One hundred fifty-three patients were recruited and tested for classical AD CSF biomarkers- Amyloid-ß42 and tau proteins - and novel candidate biomarkers - neurofilament (NF-) light and microRNA (miR) -21, -125b, -146a, and -222.All dementia patients had significantly higher concentrations of NF-light compared to CNS, with the TP group displaying the highest NF-light values. A significant inverse correlation was also observed between NF-light and cognitive impairment. Of the four miRNAs analyzed, miR-222 levels were significantly increased in VD patients compared to both CNS and AD. In addition, while NF-light showed a better diagnostic performance than miR-222 and classical AD biomarkers in differentiating TP and VD from CNS, classical AD biomarkers revealed higher performance in discriminating AD from non-AD disorders.Overall, our results suggest that CSF NF-light and miR-222 are promising biomarkers that may help to diagnose non-AD disorders.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom